Definity, an imaging agent used as contrast medium in echo cardiogram, has been launched in India by JB Chemical & Pharmaceuticals Ltd.
Definity is an ultrasound contrast imaging agent that is indicated in India for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber.
Definity is also useful to improve the delineation of the left ventricular endocardial border, as well as for use in patients in contrast-enhanced diagnostic ultrasound imaging to improve characterisation of focal lesions of the liver and kidney.
Definity vial ultrasound contrast imaging product has been brought in India under an exclusive multi-year marketing arrangement with Lantheus Medical Imaging.
“We are proud to partner with Lantheus Medical Imaging to launch Definity in India. Definity is a strategic fit for JBCPL and its addition to our product portfolio underscores our strength and continued commitment to the diagnostic medical imaging market,” said Pranabh Mody, president, J B Chemicals & Pharmaceuticals.
The introduction of Definity in India reinforces the important role this diagnostic imaging agent can play in helping physicians across the globe make informed decisions about patient treatment and care.
Definity contains perflutren lipid microsphere injectable suspension is an ultrasound contrast agent for use in patients with suboptimal cardiograms.
In India, the product is also indicated for use in patients to improve the characterisation of focal lesions of the liver and kidney. Since its launch in 2001, activated Definity has been administered to more than 2.5 million patients in the United States.
Definity is currently marketed in North America, Australia and New Zealand, parts of the Pacific Rim, and several countries in the Middle East.